RxDoctor Payments Data

Dany Jacob, MD

Interventional Cardiology · Kansas City, MONPI 1801150313

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (58.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 79.8% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $23,626, 8.4 times the $2,815 reported in 2019.

$35,216in general payments, 2019–2025

Across 270 payments — averaging $130.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$28K
  • Medtronic$3K
  • Boston Scientific$2K
  • Asahi Intecc USA, Inc.$838
  • Shockwave Medical, Inc$423
  • Penumbra, Inc.$288
  • plus $812 from 7 others
$18,200in research payments, 2019–2025

Across 1 payment — averaging $18,200 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genetesis, Inc.$18K

What the payments were for

  • Consulting fees$20,46358%
  • Speaking & faculty fees$290%
  • Travel & lodging$2,2506%
  • Food & beverage$12,45535%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott172$28,116
Medtronic(2 entities)37$2,819
Boston Scientific21$1,920
Asahi Intecc USA, Inc.17$838
Shockwave Medical, Inc4$423
Penumbra, Inc.11$288
Inari Medical, Inc.1$231
Osprey Medical Inc2$175
Livanova USA, Inc.1$131
Amgen1$123
Edwards Lifesciences1$113
CSL Behring1$20
Abiomed1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,216 in reported general payments places this provider in the 80th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$123,082
Medicare patients
510
Services billed
1,138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban157$171,810
Repatha SureclickEvolocumab45$50,088
JardianceEmpagliflozin19$22,237
XareltoRivaroxaban26$22,058
Praluent PenAlirocumab15$7,180
ClopidogrelClopidogrel Bisulfate209$3,745
Dofetilide19$3,150
Candesartan Cilexetil27$2,596
Ranolazine ErRanolazine23$2,031
Nebivolol Hcl43$1,954
Atorvastatin Calcium189$1,838
Ezetimibe48$1,361
Diltiazem 24hr Er (Cd)Diltiazem Hcl60$1,275
Rosuvastatin Calcium81$1,130
Metoprolol Succinate121$1,095

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →